These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15605442)

  • 1. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties.
    Ishii K; Saito Y; Itai S; Nemoto M; Takayama K; Nagai T
    Drug Dev Ind Pharm; 1998 Feb; 24(2):129-37. PubMed ID: 15605442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin.
    Nakagawa Y; Itai S; Yoshida T; Nagai T
    Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):725-8. PubMed ID: 1535292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarithromycin and azithromycin: new macrolide antibiotics.
    Piscitelli SC; Danziger LH; Rodvold KA
    Clin Pharm; 1992 Feb; 11(2):137-52. PubMed ID: 1312921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and stability of erythromycin delayed release tablets.
    Ogwal S; Xide TU
    Afr Health Sci; 2001 Dec; 1(2):90-6. PubMed ID: 12789122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new macrolactones: clarithromycin (Biaxin) and azithromycin (Zithromax).
    Peltier K
    Conn Med; 1992 Jul; 56(7):371-4. PubMed ID: 1330429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of comparative bioavailability studies of marketed drugs in drug control. An example with erythromycin stearate.
    Venho VM; Palva ES; Konno K; Stenfors E
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):445-7. PubMed ID: 3683018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats].
    Yoshida H; Furuta T
    Jpn J Antibiot; 1999 Jul; 52(7):497-503. PubMed ID: 10516929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.
    Periti P; Mazzei T
    J Chemother; 1999 Feb; 11(1):11-27. PubMed ID: 10078776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.
    Gill CJ; Abruzzo GK; Flattery AM; Smith JG; Jackson J; Kong L; Wilkening R; Shankaran K; Kropp H; Bartizal K
    J Antibiot (Tokyo); 1995 Oct; 48(10):1141-7. PubMed ID: 7490222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary disposition of erythromycin, azithromycin, and clarithromycin in foals.
    Suarez-Mier G; Giguère S; Lee EA
    J Vet Pharmacol Ther; 2007 Apr; 30(2):109-15. PubMed ID: 17348895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
    Ito K; Ogihara K; Kanamitsu S; Itoh T
    Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii).
    Wimsatt JH; Johnson J; Mangone BA; Tothill A; Childs JM; Peloquin CA
    J Zoo Wildl Med; 1999 Mar; 30(1):36-43. PubMed ID: 10367642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new insight into solid-state conformation of macrolide antibiotics.
    Miroshnyk I; Mirza S; Zorky PM; Heinämäki J; Yli-Kauhaluoma J; Yliruusi J
    Bioorg Med Chem; 2008 Jan; 16(1):232-9. PubMed ID: 17936632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters.
    Ishii K; Katayama Y; Itai S; Ito Y; Hayashi H
    Biol Pharm Bull; 1995 Jun; 18(6):882-6. PubMed ID: 7550125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction.
    Sketris IS; Wright MR; West ML
    Pharmacotherapy; 1996; 16(2):301-5. PubMed ID: 8820476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New macrolide antibiotics: clarithromycin and azithromycin.
    Stott GA
    Am Fam Physician; 1992 Sep; 46(3):863-9. PubMed ID: 1325106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating the barriers to bioavailability of macrolide antibiotics in the rat.
    Padovan J; Ralić J; Letfus V; Milić A; Bencetić Mihaljević V
    Eur J Drug Metab Pharmacokinet; 2012 Sep; 37(3):163-71. PubMed ID: 22113743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pharmacokinetics of erythromycin propionate-N-acetylcysteinate: comparative evaluation with erythromycin stearate and N-acetylcysteine.
    De Bernardi M; Feletti F; Gazzani G; Fregnan GB
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):444-7. PubMed ID: 3198299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat.
    al-Humayyd MS
    Chemotherapy; 1997; 43(2):77-85. PubMed ID: 9084915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.